eMedicine Specialties > Pediatrics: Surgery > General Surgery

Surgical Aspects of Cystic Fibrosis and Meconium Ileus: Treatment

Author: Michael S Irish, MD, Assistant Professor, Department of Surgery, The University of Iowa; Consulting Pediatric Surgeon, Department of Pediatric Surgery, Blank Children's Hospital and Children's Hospital Physicians Group
Coauthor(s): Philip M Bovet, DO, MPH, Resident, Department of Pediatric Surgery, Blank Children's Hospital
Contributor Information and Disclosures

Updated: Jul 31, 2006

Treatment

Medical Therapy

Manage both simple and complicated MI in newborns as an intestinal obstruction. Perform resuscitative measures, including mechanical respiratory support, if necessary. Initiate intravenous hydration with gastric decompression, evaluate and correct any coagulation disorders, and begin empiric antibiotic coverage. Immediately obtain a surgical evaluation when MI is suspected or diagnosed.

Gastrografin enemas

In 1969, Noblett introduced the use of Gastrografin enemas to treat 4 infants with MI. Variations on this approach are now the preferred initial method to treat uncomplicated MI.

Gastrografin, marketed by Bristol-Myers Squibb of Princeton, NJ, is meglumine diatrizoate, a hyperosmolar, water-soluble, radiopaque solution containing 0.1% polysorbate 80 (Tween 80) and 37% organically bound iodine. The solution's osmolarity is 1900 µOsm/L.

  • The reported success rate of Gastrografin enemas for patients with uncomplicated MI is 63-83%. In a 2005 analysis, the success rate was only 35% (15 out of 42 patients) for simple MI relief, while 64.2% (27) of patients needed surgery to relieve the obstruction.
  • Noblett's criteria for proceeding with this therapy require the following:
    • The initial diagnostic contrast enema must exclude other causes of neonatal distal intestinal obstruction.
    • The infant must show signs of uncomplicated MI and no clinical or radiologic evidence of complicating factors (eg, volvulus, gangrene, perforation, peritonitis, atresia of the small bowel).
    • The infant should be well prepared for the enema, with adequate fluid and electrolyte replacement and correction of hypothermia.
    • The enema must be performed under fluoroscopic control.
    • Intravenous antibiotics should be administered.
    • Close surgical supervision is imperative from the initial evaluation through the hospital course.
  • The procedure is as follows:
    • Upon instillation, fluid is drawn into the intestinal lumen to hydrate and soften the meconium mass. Both transient osmotic diarrhea and diuresis follow. Adequate resuscitation and hydration in anticipation of these fluid losses is paramount.
    • Under fluoroscopic control, infuse a 25-50% solution of Gastrografin slowly at low hydrostatic pressure through a catheter inserted into the rectum. Avoid balloon inflation to minimize the risk of rectal perforation.
    • To help deconcentrate the inspissated meconium, 1% N- acetylcysteine may be added to the enema solution. The procedure requires a slow infusion, carefully monitored under fluoroscopy.
    • Upon completion, withdraw the catheter and obtain an abdominal radiograph to exclude perforation.
    • Return the infant to the neonatal care unit for intensive monitoring and fluid resuscitation.
    • To help complete the evacuation, warm saline enemas containing 1% N- acetylcysteine may be used. This procedure usually prompts rapid passage of semiliquid meconium, which continues for 24-48 hours.
    • Obtain radiographs in 8-12 hours, or as clinically indicated, to confirm evacuation of the obstruction and to exclude late perforation.
    • A second enema may be necessary for nonoperative management of MI if evacuation is incomplete or if the first attempt at Gastrografin evacuation does not reflux contrast into dilated bowel.
    • If necessary, serial Gastrografin enemas can be performed at 6- to 24-hour intervals.
    • Surgical exploration is indicated for patients with progressive distension, signs of peritonitis, or clinical deterioration.
    • Following successful evacuation and resuscitation, Noblett suggests administering a 10% N- acetylcysteine solution (5 mL q6h) through a nasogastric (NG) tube to liquefy upper GI secretions.
    • Feedings, including supplemental pancreatic enzymes for infants with confirmed CF, may be initiated when signs of obstruction have subsided, usually within 48 hours.
  • Potential complications include the following:
    • Perforation
      • Rectal perforation can be avoided by carefully placing the catheter under fluoroscopic guidance and avoiding inflating balloon-tipped catheters. In 1987, Ein and Shandling reported a 23% perforation rate in patients treated with inflated balloon catheters.
      • Early perforation that occurs during enema administration is usually apparent under fluoroscopy. Perforation risk increases with repeated enemas.
      • Late perforation can occur 12-48 hours after the enema. Potential causes include severe bowel distension by fluid osmotically drawn into the intestine (the apparent etiology in experimental models) or by direct injury to the bowel mucosa by the contrast medium.
      • Delayed perforation associated with extensive bowel necrosis has been reported. The pathogenesis of intestinal perforation associated with necrotizing enterocolitis is believed to be the ischemia produced by intestinal distension.
    • Hypovolemic shock: Hypovolemic shock is a profound risk when delivering hypertonic enemas.
    • Ischemia: Ischemia caused by overdistension is worsened by hypoperfusion; this hypoperfusion is caused by the hypovolemia that results from poor fluid resuscitation. Adequate fluid resuscitation (ie, 150 mL/kg/d minimum), including anticipated fluid losses from osmotic diarrhea and diuresis, is mandatory.

Surgical Therapy

A number of surgical approaches to treat uncomplicated MI have been proposed over the years; variable success rates have been achieved. Individualize the approach for each infant.

The goal of operative management in simple uncomplicated MI is to evacuate meconium from the intestine while preserving maximal intestinal length.

Surgery is always indicated for complicated MI. Complicated MI requires resection more often than simple MI and may require temporary stomas.

The following complications require surgical management:

  • Persistent or worsening abdominal distension
  • Persistent bowel obstruction
  • Enlarging abdominal mass
  • Intestinal atresia
  • Volvulus
  • Perforation
  • Meconium cyst formation with peritonitis
  • Bowel necrosis

Intraoperative Details

Several variations of the technique used by Hiatt and Wilson have involved placing indwelling ostomy tubes for postoperative bowel irrigation decompression and/or feeding. In 1970, O'Neill described success with tube enterostomy, with and without resection. In 1981, Harberg described a similar procedure using a T-tube enterostomy. In either situation, begin irrigations on the first postoperative day; after successfully clearing the obstruction (ie, 7-14 d), the physician may remove the tube and allow the enterocutaneous fistula to close spontaneously.

Subsequent surgical techniques have revolved around resection, anastomosis, and enterostomy, through which postoperative irrigations can be delivered. The Mikulicz double-barreled enterostomy first reported by Gross in 1953, has the following distinct advantages:

  • The procedures reduce operating and anesthetic times because complete evacuation of inspissated meconium is unnecessary.
  • The procedures avoid intra-abdominal anastomosis, which eliminates the risk of anastomotic leakage.
  • The bowel can be opened following complete closure of the abdominal wound, which reduces intraperitoneal contamination risk.

Following surgery, solubilizing agents can be administered through the proximal or distal limbs of the stoma, per rectum, or by NG tube. In the classic description, a crushing clamp may be applied to the 2 limbs to create continuity for distal flow of intestinal fluids.

Disadvantages of this and other procedures employing resection and stoma(s) are potential postoperative fluid losses through high-volume stomas, bowel shortening by resection, and the need for a second procedure to reestablish intestinal continuity.

A distal chimney enterostomy, described by Bishop and Koop in 1957, involves resection with anastomosis between the end of the proximal segment and the side of the distal segment of bowel, approximately 4 cm from the opening of the distal segment. The open end is brought out as the ileostomy. This technique allows normal GI transit while providing a means for managing distal obstruction through the ileostomy, should it occur.

The reverse of the Bishop-Koop enterostomy is the proximal enterostomy described by Santulli in 1961.

  • In this technique, following resection, the end of the distal limb is anastomosed to the side of the proximal limb. The end of the proximal limb is brought out as the enterostomy. This arrangement enhances proximal irrigation and decompression, and evacuation of the proximal small bowel at the time of surgery is unnecessary.
  • As with distal chimney enterostomy, a catheter is placed for access to the distal limb. The catheter exits through the stoma to provide a means to irrigate the distal bowel.
  • This technique's apparent disadvantage is the presence of a high-output stoma and the inherent risk of dehydration.
  • Take care to replenish fluids, electrolytes, and nutrients in accordance with the stomal output.
  • Reinstallation of stomal output from the proximal to the distal limb often is performed via the indwelling catheter.

Resection with primary anastomosis was suggested first by Swenson in 1962. Initially, this technique had difficulties and complications with leakage from the anastomosis. More recently, Chappell in 1977 and Mabogunje in 1982 have reported improved results. These authors emphasize the necessity of adequately resecting the compromised bowel, completely evacuating proximal and distal meconium, and preserving an adequate blood supply to the anastomosis.

The author prefers a modification of the technique originally described by Gross in 1953 to manage infants with uncomplicated MI.

  • This modified technique begins by performing a celiotomy with a muscle-sparing horizontal incision just above the umbilicus.
  • Upon exploration, a decision is made, based upon the viability and length of the bowel, either to create an enterotomy for irrigation and evacuation of the meconium or to resect the segment of impacted intestine.
  • The author then creates side-by-side separate enterostomies without creating a common wall.
  • Stomas are placed within the abdominal incision to the right; these may be covered with a single ostomy collecting device.
  • Postoperatively, each stoma may be irrigated to remove residual meconium.
  • Instillation of dilute enteral feedings high in glutamine, via the distal stoma, may also be performed to stimulate growth of the unused distal bowel.
  • Intestinal continuity is usually restored within 6 weeks if bowel function resumes and the infant tolerates oral feedings.

Due to associated hepatic pathology, a liver transplant may be indicated. A study of 10 patients with CF who received orthotopic liver transplants (OLTX) found a mortality rate of 40%; all 4 patients who died had a history of MI. This is contrasted with the 6 patients who survived; 4 of these 6 (67%) had a history of MI. OLTX mortality was also associated with worse nutrition and development, a need for preoperative pancreatic enzymes, a higher incidence of pancreatic insufficiency, being transplanted at an older age, and, probably most important, a longer waiting time until transplantation.

A case study of a 7-month-old boy with CF who needed a new liver and small intestine supports that early multivisceral transplantation can be safely performed. The boy weighed 6 kg ( <5th percentile at age of transplantation) and gained weight to 12 kg (75th percentile at age 3.6 y). Overall, intestinal transplant survival rate is 77% and 64% for the first year and 5 years, respectively, while the 1-year graft survival rate is 67%, and the 5-year graft survival rate is 37%. Additionally, 87% of patients who receive intestinal transplant no longer require total parenteral nutrition (TPN).

Postoperative Details

Initial postoperative management involves ongoing resuscitation. Carefully replace the fluid losses caused by surgery and by preoperative diuresis and diarrhea (if a Gastrografin enema was attempted). Adjust ongoing maintenance fluids and replace insensible fluids lost, as well as GI losses (ie, losses from NG suction and ileostomy).

Instillation of N -acetylcysteine via an NG tube or via ileostomy helps solubilize residual meconium.

As soon as possible (ie, 6 wk) close the stomas placed in the course of surgical management to help avoid prolonged problems with fluid, electrolyte, and nutritional losses.

Follow-up

Nutritional management

Infants with uncomplicated MI and CF may receive breast milk or routine infant formula, enzymes, and vitamins. Use caution when prescribing enteric enzyme medication to patients with MI and CF. Reported complications include fibrosing colonopathy from excessive enzyme doses and distal intestinal obstruction syndrome (DIOS). Generic substitutions for proprietary medications have also been associated with treatment failures.

Patients who have a complicated surgical course require either continuous enteral feedings or TPN. The author recommends predigested infant formulas (eg, Alimentum, Pregestimil), for enteral feeding.

Prestenotic dilation of the small bowel caused by a meconium obstruction theoretically could cause mucosal damage that, in turn, could contribute to poor peristalsis or malabsorption. Patients who have had complicated MI and/or sizable bowel resection and who are fed enterally may tolerate continuous feedings better than bolus feedings.

Because bowel mucosa may or may not be damaged by stasis, begin feedings with predigested diluted formula, usually half strength, at low volume. Once this diluted formula is well tolerated, the physician may increase formula strength and then volume. During this process, look for signs of feeding intolerance (eg, abdominal distention, heme-positive stools, increasing emesis).

Once oral feedings begin, administer oral pancreatic enzymes, even with predigested formulas, starting at 2000-4000 lipase units per 120 mL of full-strength formula. For example, an infant who weighs 2.5 kg and who is receiving formula at 4 mL/kg/h should be administered half of a 4000-lipase Pancrease capsule PO q12h. Capsules containing enteric-coated microspheres can be opened. Capsule contents can be mixed with applesauce and administered orally.

Do not crush the microcapsules because crushing exposes the enzymes to stomach acid during oral administration, which destroys the enzymes.

Uncrushed pancreatic enzymes should be administered even with formulas that contain medium-chain triglyceride (MCT) oil.

If pancreatic enzymes cause skin breakdown, a zinc oxide ointment (Desitin) can be applied to perianal skin.

Complications

  • Complicated MI may cause volvulus, atresia, necrosis, perforation, meconium peritonitis, and pseudocyst formation.
  • Infants with MI are at risk for cholestasis, particularly if they have received or are receiving TPN. Monitor alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin levels weekly.
  • Infants who have had significant bowel resection (ie, >33%) may be difficult to manage, especially if the ileocecal valve has been resected. In addition, an ileostomy may lead to excessive fluid and sodium losses. Take down ostomies as soon as possible. In the interim, if access to the distal defunctionalized bowel is feasible, administer ostomy-drip feeds of glutamine-enriched formula at low volumes to enhance bowel growth and to help prevent bacterial translocation.
  • Gastric acid hypersecretion occurs in patients with short-bowel syndrome.
    • The acidic intestinal environment inactivates pancreatic enzymes and prevents dissolution of enteric-coated microcapsules. Histamine 2 receptor blockers may be used as an adjunct to pancreatic enzyme therapy in patients who have had significant bowel resections.
    • Patients with the double burden of excessive sweat and intestinal sodium losses may require compensation for total body sodium deficit. Measure urine sodium levels in infants with ileostomies, especially those who do not grow, even if serum sodium levels are within the reference range. Infants with urine sodium levels less than 10 mEq/L need sodium (and possibly bicarbonate) supplementation.
  • Pulmonary complications include the following:
    • Although clinical lung disease usually does not develop early, mucus plugging and atelectasis can occur. Immediately postoperatively, initiate vigorous prophylactic pulmonary care with chest physiotherapy. Do not use the head-down position because this increases the risk of gastroesophageal reflux (GER) and aspiration.
    • Infants should receive nebulized albuterol (2.5 mg bid), followed by chest physiotherapy.
    • Prophylactic antibiotics are unnecessary. Antibiotic therapy, if needed, should be based on respiratory tract cultures.

Other potential complications of cystic fibrosis

Gastroesophageal reflux

GER occurs with increased prevalence in patients with CF, and reflux may also exacerbate the respiratory status of the patient with CF. Pathological reflux, ie, endoscopic and histologic esophagitis, is present in over 50% of patients with CF. Most patients with CF have an abnormal quantity of reflux as defined by pH probe, and it has been reported with prominent respiratory symptoms. Clearly, early diagnosis and treatment of this condition is of prime importance if the complications of pathological reflux are to be curtailed and respiratory function maximized.

The particular mechanism of GER in CF is unclear, but a number of factors may contribute to the increased susceptibility of this patient group to the development of pathological GER. First, most reflux episodes in CF occur during transient lower esophageal sphincter (LES) relaxations. These transient relaxations are increased during distension of the gastric fundus, a feature that can predispose these patients to reflux especially when receiving large supplemental bolus feeds. This cycle of events may be further exacerbated in the event of poor gastric emptying. Gastric emptying of liquids was initially thought to be delayed in patients with CF.

Second, the head-down posture adopted during chest physiotherapy places gastric liquid content in an optimum position at the LES for reflux in the event of a transient period of relaxation. Associated coughing and forced expiration, which both increase the abdominothoracic pressure gradient, also facilitates reflux action.

Last, medications such as theophylline and beta-adrenergic drugs, used in the treatment of respiratory disease in patients with CF, are known to decrease the resting tone in the LES and could conceivably facilitate reflux activity.

Biliary tract disease

Gallbladder disease is prevalent in the CF population, with abnormal oral cholecystograms in 46% and cholelithiasis in 12%. Abnormalities described in patients with CF include, a microgallbladder containing thick colorless "white bile" with occlusion of the cystic duct, gallstones, biliary dyskinesia, and sclerosing cholangitis. Bile acid metabolism is disturbed in patients with pancreatic insufficiency who are not receiving adequate pancreatic enzyme supplementation. Bile acids are likely bound to malabsorbed fat and, as a result, are lost in feces, which in turn depletes the bile acid pool and supersaturates cholesterol in the gallbladder. This condition promotes stone formation.

Many patients with CF and gallbladder sludge or stones are asymptomatic, but approximately 4% have the classic symptomatology of cholecystitis. A laparoscopic cholecystectomy is the treatment of choice in such cases because postoperative pain is less and therefore pulmonary compromise is less when compared to the classic open technique. The role of cholecystectomy in patients with asymptomatic gallstones remains unclear.

Distal intestinal obstruction

DIOS (formally called meconium ileus equivalent) is a recurrent postneonatal partial or complete intestinal obstruction unique to patients with CF. Most cases occur in adolescents and adults, but all age groups can be affected with an overall incidence of approximately 15%.

The exact etiology is unknown, but these patients are more likely to have a history of steatorrhea from pancreatic exocrine insufficiency despite adequate enzyme therapy. One study also showed that, of 27 patients with DIOS, 17 (63%) had a history of MI as an infant. A number of aspects peculiar to gastrointestinal function of patients with CF may help, in part, to explain this syndrome. These include abnormal intestinal mucins, abnormal intraluminal water and electrolyte content, and inherently slow intestinal motility. The latter may be because neurotensin, a gastrointestinal hormone that delays motility, is secreted from the distal ileum when unabsorbed fat reaches that location. Some additional precipitating factors may be relative dehydration, especially in a postoperative period, inadequate enzyme supplementation, and changes in diet.

The cardinal features of the syndrome are cramping abdominal pain, often localized to the right lower quadrant (RLQ), a palpable mass in the RLQ, and decreased frequency of defecation. Different degrees of obstruction are present, from partial, which is most common, to complete with vomiting, distension, and absolute constipation. Colicky pain may be provoked by meals, which may then result in anorexia as a method to avoid further pain. Physical examination in uncomplicated DIOS usually reveals a tender mass in the RLQ with no evidence of peritonitis. No fecal impaction or dehydrated stool is noted on rectal examination, and the stool is heme negative.

The nonspecific nature of DIOS, with no pathognomonic radiologic features, means that an accurate diagnosis of abdominal pain in the patient with CF is not easy. Plain supine and erect abdominal radiography is still, however, the most helpful initial investigation when the diagnosis is suspected. This shows bubbly granular material in the right iliac fossa and variable degrees of small-bowel obstruction, ie, air-fluid levels with proximal small-bowel dilatation. Plain radiography supports, but does not prove, the diagnosis. Inspissated material in the right iliac fossa can also be demonstrated with a water-soluble contrast enema. In doing so, intussusception can be excluded and the investigation itself may prove therapeutic in some cases of DIOS.

Particular difficulty is faced in the event of partial small-bowel obstruction caused by adhesions from previous abdominal surgery or appendiceal disease, which occurs in 1.5-2% of patients with CF, less than the general population occurrence of 8.6%. Abdominal pain is a common symptom of patients with CF and, because they are often already being treated with antibiotics and steroids, the classic clinical signs and symptoms of appendicitis are often masked and the critical diagnosis missed. This results in a high incidence of perforation and substantial morbidity in this patient group. Despite the blunting of clinical signs, evidence of pyrexia and a leukocytosis may still be present.

Depending on the appendix location, a contrast enema may show deformity of the cecum with an associated mass effect and not the typical inspissated material features of DIOS. Abdominal ultrasonography or, if necessary, CT scanning shows free fluid or an abscess collection in the region of the cecum. In such cases, treatment should then proceed with appendectomy. If the diagnosis is still in doubt, the surgeon could opt to start with a laparoscopic investigation and then proceed appropriately in light of the findings.

In the absence of partial small-bowel obstruction due to adhesions, appendiceal disease, or complete obstruction, DIOS is suitable for a trial of medical management. After adequate rehydration, a balanced polyethylene glycol–electrolyte solution, such as GoLYTELY or Colyte, can be administered orally or by NG tube. The dose is 20-40 mL/kg/h with a maximum of 1200 mL/h. Prokinetic agents, such as metoclopramide, can be used to limit the amount of nausea and bloating. Successful treatment is judged by the passage of stool, resolution of symptoms, and the disappearance of a previously palpable right iliac fossa mass. Sequential plain abdominal radiography helps to document the resolution of DIOS, but if symptoms persist, then the differential diagnosis already outlined must be reconsidered.

The use of enemas at the diagnostic stage is outlined. Contrast enemas should also be used for patients with emesis due to DIOS after placement of a NG tube for gastric suction. As long as the patient remains clinically stable, the contrast enemas may be repeated at intervals of several hours over several days. However, careful monitoring of the patient must be initiated before, during, and after the procedure because large fluid and electrolyte shifts can be induced by the contrast material.

When complete obstruction or evidence of peritonitis is present, surgical intervention is necessary and all oral or rectal therapies are contraindicated. A NG tube should be passed to help with decompression and adequate resuscitative measures initiated. At laparotomy, the bowel wall feels thickened and filled with tenacious material. It can be decompressed and irrigated with Gastrografin, usually via a small catheter placed through the appendix stump, as previously described for meconium ileus. Leaving an irrigating tube in situ is also possible to irrigate the bowel postoperatively.

Gastrointestinal neoplasms

The overall risk of cancer in patients with CF is similar to that of the general population; however, risk of digestive tract cancers is increased. These include tumors of the esophagus, stomach, small intestine, large intestine, liver or biliary tract, and pancreas.

The differential localization and expression of the cystic fibrosis transmembrane conductance regulator gene may have a role to play in the neoplastic disease process. Furthermore, increased cellular turnover in response to the persistent irritation of GER, gallstones, or steatorrhea in digestive tract organs may also offer an explanation to these findings.

Fibrosing colonopathy

Fibrosing colonopathy is a newly described entity in children with CF. A longitudinal study showed that, of the children with CF who developed fibrosing colonopathy, 89% (8) of patients went to surgery, and 63% (5) of them received a subtotal colectomy. Findings at laparotomy (in children with CF who presented with presumed DIOS that did not respond to medical therapy) include colonic strictures with histopathological changes of postischemic ulceration repair, with mucosal and submucosal fibrosis, destruction of the muscularis mucosa, and eosinophilia. In some patients, a change from conventional enteric-coated pancreatic enzymes to high-strength products 12-15 months before presentation has been described. In the largest case-control study reported, the absolute dose of pancreatic enzymes, rather than the type of enzyme, was the strongest predictor of fibrosing colonopathy.

The diagnosis of fibrosing colonopathy should be considered in patients with CF who have been exposed to high doses of pancreatic enzymes and present with symptoms of abdominal pain, distension, chylous ascites, change in bowel habit, or failure to thrive. Continued diarrhea may also be a prominent feature, which unfortunately may prompt the family to increase supplemental enzymes further. On occasion, the diarrhea may be bloody. A barium enema may reveal mucosal irregularity, loss of haustral markings with a foreshortened colon with varying degrees of stricture formation. In some cases, the whole colon has been involved. Colonoscopy may show an erythematous mucosa and areas of narrowing, from which taking multiple forcep-pinch biopsies is advisable.

Initial management should reduce enzyme dosage to the recommended levels of 500-2500 lipase units/kg per meal. This should be accompanied with adequate nutritional supplementation, which may be enteral elemental feeding or even total parenteral nutrition for a time. Those patients who show signs of unrelenting failure to thrive, obstruction, uncontrollable diarrhea, or chylous ascites then need surgical intervention.

When surgery is planned electively for patients with intractable symptoms, gentle bowel preparation can be administered preoperatively. The aim of surgical intervention is to resect the affected bowel and make a primary anastomosis. Unfortunately, this is not possible in the event of pancolonic or rectal involvement, and as a result, the patient requires an ostomy. This is often the safest option; patients and parents must be fully aware and prepared for it preoperatively. Whether this condition completely resolves with a reduction in enzyme dosage and surgical resection is unclear, so the operated group also requires regular follow-up for any signs of deterioration.

Rectal prolapse

Rectal prolapse occurs in approximately 20%-23% of patients with CF. The initial prolapse occurs most commonly in patients aged 1-3 years and can be recurrent in nature. It may also be the sole presenting feature of a new patient with CF in about 4-8% of all cases.

Factors that directly predispose this group to prolapse include constipation, diarrhea with increased frequency and volume of movement, malabsorption, and colonic distension. Indirect contributors relate to increased intra-abdominal pressure caused by coughing or pulmonary hyperinflation.

Initial management involves manually reducing the prolapse. Medical management to maximize fat absorption then aids the overall control. Reassure parents that the number of prolapse episodes is likely to reduce with age. However, further intervention is warranted in a small group when they have persistent pain or incontinence with each episode of prolapse.

The acute prolapse is easily reduced if action is taken promptly before edema formation. Parents can be taught to grasp the herniated bowel with the fingertips of a gloved hand and apply circumferential pressure with an inward push. Sustained pressure may be required to achieve full reduction. If prolapse immediately recurs, then the buttocks can be strapped together with adhesive tape for 7-14 days.

Recurrent prolapse can be treated by a rectal submucosal injection. The procedure is performed under general anesthetic after the rectum has been emptied with a suppository. With the patient in the lithotomy position, the needle is inserted through the skin just outside the mucocutaneous junction and guided into position by a finger placed in the rectum. As the needle is slowly withdrawn, 2-3 mL of 5% phenol in almond oil or hypertonic sodium chloride solution (30%) are injected in a linear track into 4 different quadrants. A single treatment controls approximately 90% of cases. Linear electrocauterization in the 4 quadrants has also been described to produce a perirectal inflammation. This technique requires a longer hospital stay and may be complicated with rectal bleeding and or rectal stenosis.

When all conservative options are exhausted, a surgical approach may then be considered. However, many different operations have been described to control rectal prolapse. Through a transabdominal approach, the rectum can be fixed to the hollow of the sacrum by a prosthetic or fascia lata graft sutured to the bowel and the presacral fascia, thus creating a new pelvic floor. Other operations include rectal suspension and levator ani muscle repair through a posterior sagittal approach. The diversity of options highlights the unsatisfactory results often achieved in these difficult cases.

More on Surgical Aspects of Cystic Fibrosis and Meconium Ileus

Overview: Surgical Aspects of Cystic Fibrosis and Meconium Ileus
Workup: Surgical Aspects of Cystic Fibrosis and Meconium Ileus
Treatment: Surgical Aspects of Cystic Fibrosis and Meconium Ileus
Follow-up: Surgical Aspects of Cystic Fibrosis and Meconium Ileus
References
[ CLOSE WINDOW ]

References

  1. Allan JL, Robbie M, Phelan PD, Danks DM. Familial occurrence of meconium ileus. Eur J Pediatr. Feb 1981;135(3):291-2. [Medline].

  2. Anderson D. Cystic fibrosis of the pancreas and its relationship to celiac disease. Am J Dis Child. 1938;56:344-99.

  3. Andrassy R, Nirgiotis J. Meconium disease of infancy: meconium ileus, meconium plug syndrome, and meconium peritonitis. Pediatric Surgery. 1990;331-40.

  4. Anguiano A, Oates RD, Amos JA, et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA. Apr 1 1992;267(13):1794-7. [Medline].

  5. Bahado-Singh R, Morotti R, Copel JA, Mahoney MJ. Hyperechoic fetal bowel: the perinatal consequences. Prenat Diagn. Oct 1994;14(10):981-7. [Medline].

  6. Bali A, Stableforth DE, Asquith P. Prolonged small-intestinal transit time in cystic fibrosis. Br Med J (Clin Res Ed). Oct 8 1983;287(6398):1011-3. [Medline].

  7. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. Feb 21 1992;68(4):809-18. [Medline].

  8. Benacerraf BR, Chaudhury AK. Echogenic fetal bowel in the third trimester associated with meconium ileus secondary to cystic fibrosis. A case report. J Reprod Med. Apr 1989;34(4):299-300. [Medline].

  9. Bishop H, Koop C. Management of meconium ileus: resection, Roux-en-Y anastomosis and ileostomy irrigation with pancreatic enzymes. Ann Surg. 1957;145:410-4.

  10. Boat T, Welsh M, Beaudet A. Cystic Fibrosis. In: The Metabolic Basis of Inherited Disease. New York, NY:. McGraw-Hill;1989:2649-80.

  11. Bodian M. Congenital disorder of mucous production-mucosis. Fibrocystic Disease of the Pancrease. 1953.

  12. Borowitz D, Wegman T, Harris M. Preventive care for patients with chronic illness. Multivitamin use in patients with cystic fibrosis. Clin Pediatr (Phila). Dec 1994;33(12):720-5. [Medline].

  13. Borowitz D, Scheig R. Recurrent abdominal pain in a patient with cystic fibrosis and type IV hyperlipidemia. J Pediatr Gastroenterol Nutr. May 1995;20(4):440-2. [Medline].

  14. Boue A, Muller F, Nezelof C, et al. Prenatal diagnosis in 200 pregnancies with a 1-in-4 risk of cystic fibrosis. Hum Genet. Nov 1986;74(3):288-97. [Medline].

  15. Bower TR, Pringle KC, Soper RT. Sodium deficit causing decreased weight gain and metabolic acidosis in infants with ileostomy. J Pediatr Surg. Jun 1988;23(6):567-72. [Medline].

  16. Bromley B, Doubilet P, Frigoletto FD Jr, et al. Is fetal hyperechoic bowel on second-trimester sonogram an indication for amniocentesis?. Obstet Gynecol. May 1994;83(5 Pt 1):647-51. [Medline].

  17. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr. Apr 1992;120(4 Pt 1):533-40. [Medline].

  18. Buchanan D, Rapoport S. Chemical comparison of normal meconium and meconium from patients with meconium ileus. Pediatrics. 1952;9:304-10.

  19. Burke MS, Ragi JM, Karamanoukian HL, et al. New strategies in nonoperative management of meconium ileus. J Pediatr Surg. May 2002;37(5):760-4. [Medline].

  20. Caniano DA, Beaver BL. Meconium ileus: a fifteen-year experience with forty-two neonates. Surgery. Oct 1987;102(4):699-703. [Medline].

  21. Caspi B, Elchalal U, Lancet M, Chemke J. Prenatal diagnosis of cystic fibrosis: ultrasonographic appearance of meconium ileus in the fetus. Prenat Diagn. Jun 1988;8(5):379-82. [Medline].

  22. Chappell JS. Management of meconium ileus by resection and end-to-end anastomosis. S Afr Med J. Dec 24 1977;52(27):1093-4. [Medline].

  23. Clarke LL, Grubb BR, Yankaskas JR, et al. Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc Natl Acad Sci U S A. Jan 18 1994;91(2):479-83. [Medline]. [Full Text].

  24. Colledge WH, Abella BS, Southern KW, et al. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat Genet. Aug 1995;10(4):445-52. [Medline].

  25. Dalzell AM, Freestone NS, Billington D, Heaf DP. Small intestinal permeability and orocaecal transit time in cystic fibrosis. Arch Dis Child. Jun 1990;65(6):585-8. [Medline].

  26. DeLorimier AA, Fonkalsrud EW, Hays DM. Congenital atresia and stenosis of the jejunum and ileum. Surgery. May 1969;65(5):819-27. [Medline].

  27. Dechelotte PJ, Mulliez NM, Bouvier RJ, et al. Pseudo-meconium ileus due to cytomegalovirus infection: a report of three cases. Pediatr Pathol. Jan-Feb 1992;12(1):73-82. [Medline].

  28. Denholm TA, Crow HC, Edwards WH, et al. Prenatal sonographic appearance of meconium ileus in twins. AJR Am J Roentgenol. Aug 1984;143(2):371-2. [Medline].

  29. Dicke JM, Crane JP. Sonographically detected hyperechoic fetal bowel: significance and implications for pregnancy management. Obstet Gynecol. Nov 1992;80(5):778-82. [Medline].

  30. Dolan TF Jr, Touloukian RJ. Familial meconium ileus not associated with cystic fibrosis. J Pediatr Surg. Dec 1974;9(6):821-24. [Medline].

  31. Donnison AB, Shwachman H, Gross RE. A review of 164 children with meconium ileus seen at the Children''s Hospital Medical Center, Boston. Pediatrics. May 1966;37(5):833-50. [Medline].

  32. Duchatel F, Muller F, Oury JF, et al. Prenatal diagnosis of cystic fibrosis: ultrasonography of the gallbladder at 17-19 weeks of gestation. Fetal Diagn Ther. Jan-Feb 1993;8(1):28-36. [Medline].

  33. Durie PR, Newth CJ, Forstner GG, Gall DG. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzyme supplement. J Pediatr. May 1980;96(5):862-4. [Medline].

  34. Ein SH, Shandling B, Reilly BJ, Stephens CA. Bowel perforation with nonoperative treatment of meconium ileus. J Pediatr Surg. Feb 1987;22(2):146-7. [Medline].

  35. Escobar MA, Grosfeld JL, Burdick JJ, et al. Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. Surgery. Oct 2005;138(4):560-71; discussion 571-2. [Medline].

  36. Estroff JA, Parad RB, Benacerraf BR. Prevalence of cystic fibrosis in fetuses with dilated bowel. Radiology. Jun 1992;183(3):677-80. [Medline].

  37. Fakhry J, Reiser M, Shapiro LR, et al. Increased echogenicity in the lower fetal abdomen: a common normal variant in the second trimester. J Ultrasound Med. Sep 1986;5(9):489-92. [Medline].

  38. Fanconi G, Uehlinger E, Knauer C. Das Coeliakiesyndrom bei angeborener zystischer pancreas fibromatose und bronchiektasien. Wien Med Wochenschr. 1936;27/28:753-6.

  39. Farber S. The relation of pancreatic achylia to meconium ileus. J Pediatr. 1944;24:387-92.

  40. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. Jan 1993;122(1):1-9. [Medline].

  41. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med. May 1 1997;336(18):1283-9. [Medline].

  42. Fitzgerald R, Conlon K. Use of the appendix stump in the treatment of meconium ileus. J Pediatr Surg. Sep 1989;24(9):899-900. [Medline].

  43. Forouzan I. Fetal abdominal echogenic mass: an early sign of intrauterine cytomegalovirus infection. Obstet Gynecol. Sep 1992;80(3 Pt 2):535-7. [Medline].

  44. Foulkes AG, Harris A. Localization of expression of the cystic fibrosis gene in human pancreatic development. Pancreas. Jan 1993;8(1):3-6. [Medline].

  45. Fridell JA, Mazariegos GV, Orenstein D, et al. Liver and intestinal transplantation in a child with cystic fibrosis: a case report. Pediatr Transplant. Jun 2003;7(3):240-2. [Medline].

  46. Gillis D, Grantmyre E. The meconium plug syndrome and Hirschsprung's Disease. Can Med Assoc J. 1965;92:225-7.

  47. Glanzmann E. Dysporia entero-bronco-pancreatica congenita familiaris. Ann Paediat. 1946;166:289.

  48. Goldstein RB, Filly RA, Callen PW. Sonographic diagnosis of meconium ileus in utero. J Ultrasound Med. Nov 1987;6(11):663-6. [Medline].

  49. Gollin Y, Shaffer W, Gollin G. Increased abdominal echogenicity in utero a marker for intestinal obstruction. Am J Obstet Gynecol (Abstract No. 181). 1993;168:349.

  50. Grantmyre EB, Butler GJ, Gillis DA. Necrotizing enterocolitis after Renografin-76 treatment of meconium ileus. AJR Am J Roentgenol. May 1981;136(5):990-1. [Medline].

  51. Green M, Clarke J, Shwachman H. Studies in cystic fibrosis of the pancreas: protein pattern in meconium ileus. Pediatrics. 1958;21:635.

  52. Gross R. Intestinal Obstruction in the Newborn Arising from Meconium Ileus. The surgery of infants and childhood. 1953;175-191.

  53. Harberg FJ, Senekjian EK, Pokorny WJ. Treatment of uncomplicated meconium ileus via T-tube ileostomy. J Pediatr Surg. Feb 1981;16(1):61-3. [Medline].

  54. Hasty P, O''Neal WK, Liu KQ, et al. Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene. Somat Cell Mol Genet. May 1995;21(3):177-87. [Medline].

  55. Hendeles L, Dorf A, Stecenko A. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA. May 9 1990;263(18):2459-61. [Medline].

  56. Hendeles L. Use bioequivalency rating to select generics. Am Pharm. Oct 1989;NS29(10):6. [Medline].

  57. Herson R. Meconium ileus. Radiology. 1957;68:568.

  58. Hiatt R, Wilson P. Therapy of meconium ileus: report of 8 cases with review of the liter. Surg Gynecol Obstet. 1948;87:317-27.

  59. Hurwitt E. Meconium ileus associated with stenosis of the pancreatic ducts. Am J Dis Child. 1942;64:443-54.

  60. Hyman PE, Everett SL, Harada T. Gastric acid hypersecretion in short bowel syndrome in infants: association with extent of resection and enteral feeding. J Pediatr Gastroenterol Nutr. Mar-Apr 1986;5(2):191-7. [Medline].

  61. Irish MS, Gollin Y, Borowitz DS. Meconium Ileus antenatal diagnosis and perinatal care. 1996;8:79-83.

  62. Irish MS, Ragi JM, Karamanoukian H, et al. Prenatal diagnosis of the fetus with cystic fibrosis and meconium ileus. Pediatr Surg Int. Jul 1997;12(5-6):434-6. [Medline].

  63. Irish MS, Glick PL, Borowitz DS, Kantos M. An asfaliogenic complication arising from profit-motivated decision-making. Pediatrics. Mar 1997;99(3):503-4. [Medline]. [Full Text].

  64. Jarvi K, McCallum S, Zielenski J, et al. Heterogeneity of reproductive tract abnormalities in men with absence of the vas deferens: role of cystic fibrosis transmembrane conductance regulator gene mutations. Fertil Steril. Oct 1998;70(4):724-8. [Medline].

  65. Kent G, Oliver M, Foskett JK, et al. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res. Aug 1996;40(2):233-41. [Medline].

  66. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. Sep 8 1989;245(4922):1073-80. [Medline].

  67. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med. Nov 29 1990;323(22):1517-22. [Medline].

  68. Kerem E, Corey M, Kerem B, et al. Clinical and genetic comparisons of patients with cystic fibrosis, with or without meconium ileus. J Pediatr. May 1989;114(5):767-73. [Medline].

  69. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. Jun 1992;50(6):1178-84. [Medline].

  70. Lai HJ, Cheng Y, Cho H, et al. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. Mar 15 2004;159(6):537-46. [Medline].

  71. Lands L, Zinman R, Wise M, Kopelman H. Pancreatic function testing in meconium disease in CF: two case reports. J Pediatr Gastroenterol Nutr. Mar-Apr 1988;7(2):276-9. [Medline].

  72. Landsteiner K. Darmverschluss durch eingedicktes Meconium: Pancreatitis. Zentralbl Allg Pathol. 1905;16:903-7.

  73. Leonidas JC, Berdon WE, Baker DH, Santulli TV. Meconium ileus and its complications. A reappraisal of plain film roentgen diagnostic criteria. Am J Roentgenol Radium Ther Nucl Med. Mar 1970;108(3):598-609. [Medline].

  74. Leonidas JC, Burry VF, Fellows RA, Beatty EC. Possible adverse effect of methylglucamine diatrizoate compounds on the bowel of newborn infants with meconium ileus. Radiology. Dec 1976;121(3 Pt. 1):693-6. [Medline].

  75. Li Z, Lai HJ, Kosorok MR, et al. Longitudinal pulmonary status of cystic fibrosis children with meconium ileus. Pediatr Pulmonol. Oct 2004;38(4):277-84. [Medline].

  76. Lince DM, Pretorius DH, Manco-Johnson ML, et al. The clinical significance of increased echogenicity in the fetal abdomen. AJR Am J Roentgenol. Oct 1985;145(4):683-6. [Medline].

  77. Lutzger LG, Factor SM. Effects of some water-soluble contrast media on the colonic mucosa. Radiology. Mar 1976;118(3):545-8. [Medline].

  78. Mabogunje OA, Wang CI, Mahour H. Improved survival of neonates with meconium ileus. Arch Surg. Jan 1982;117(1):37-40. [Medline].

  79. Makowski GS, Nadeau FL, Hopfer SM. Single tube multiplex PCR detection of 27 cystic fibrosis mutations and 4 polymorphisms using neonatal blood samples collected on Guthrie cards. Ann Clin Lab Sci. 2003;33(3):243-50. [Medline].

  80. McPartlin JF, Dickson JA, Swain VA. Meconium ileus. Immediate and long-term survival. Arch Dis Child. Apr 1972;47(252):207-10. [Medline].

  81. Molmenti EP, Squires RH, Nagata D, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant. Apr 2003;7(2):93-7. [Medline].

  82. Noblett H. Meconium Ileus. Pediatric Surgery. 1979;3rd ed:943-51.

  83. Noblett HR. Treatment of uncomplicated meconium ileus by Gastrografin enema: a preliminary report. J Pediatr Surg. Apr 1969;4(2):190-7. [Medline].

  84. Norkina O, De Lisle RC. Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10. BMC Genet. 2005;6(1):29. [Medline]. [Full Text].

  85. Nyberg DA, Resta RG, Luthy DA, et al. Prenatal sonographic findings of Down syndrome: review of 94 cases. Obstet Gynecol. Sep 1990;76(3 Pt 1):370-7. [Medline].

  86. Nyberg DA, Dubinsky T, Resta RG, et al. Echogenic fetal bowel during the second trimester: clinical importance. Radiology. Aug 1993;188(2):527-31. [Medline].

  87. Nyberg DA, Hastrup W, Watts H, Mack LA. Dilated fetal bowel. A sonographic sign of cystic fibrosis. J Ultrasound Med. May 1987;6(5):257-60. [Medline].

  88. O''Neill JA Jr, Grosfeld JL, Boles ET Jr, Clatworthy HW Jr. Surgical treatment of meconium ileus. Am J Surg. Jan 1970;119(1):99-105. [Medline].

  89. Olsen MM, Luck SR, Lloyd-Still J, Raffensperger JG. The spectrum of meconium disease in infancy. J Pediatr Surg. Oct 1982;17(5):479-81. [Medline].

  90. Orgad S, Berkenstadt M, Achiron R, et al. Hyperechogenic bowel loops and meconium ileus in a fetus carrying the D1152H and G542X cystic fibrosis CFTR mutations. Prenat Diagn. Jul 2002;22(7):636-7. [Medline].

  91. Paulson EK, Hertzberg BS. Hyperechoic meconium in the third trimester fetus: an uncommon normal variant. J Ultrasound Med. Dec 1991;10(12):677-80. [Medline].

  92. Rescorla FJ, Grosfeld JL, West KJ, Vane DW. Changing patterns of treatment and survival in neonates with meconium ileus. Arch Surg. Jul 1989;124(7):837-40. [Medline].

  93. Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: historical notes, principles and controversies. Pediatr Transplant. Jun 2002;6(3):193-207. [Medline].

  94. Rickman P, Boeckman C. Neonatal meconium obstruction in the absence of mucoviscidosis. Am J Surg. 1965;109:173-7.

  95. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. Sep 8 1989;245(4922):1066-73. [Medline].

  96. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. Sep 8 1989;245(4922):1059-65. [Medline].

  97. Rowe MI, Furst AJ, Altman DH, Poole CA. The neonatal response to gastrografin enema. Pediatrics. Jul 1971;48(1):29-35. [Medline].

  98. Rowe MI, Seagram G, Weinberger M. Gastrografin-induced hypertonicity. The pathogenesis of a neonatal hazard. Am J Surg. Feb 1973;125(2):185-8. [Medline].

  99. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet. Mar 1996;12(3):280-7. [Medline].

  100. Santulli T. Meconium ileus. Pediatric Surgery. 1980.

  101. Santulli T, Blanc W. Congenital atresia of the intestine: pathogenesis and treatment. Ann Surg. 1961;939.

  102. Shalev J, Navon R, Urbach D, et al. Intestinal obstruction and cystic fibrosis: antenatal ultrasound appearance. J Med Genet. Jun 1983;20(3):229-30. [Medline].

  103. Snouwaert JN, Brigman KK, Latour AM, et al. A murine model of cystic fibrosis. Am J Respir Crit Care Med. Mar 1995;151(3 Pt 2):S59-64. [Medline].

  104. Stephan U, Busch EW, Kollberg H, Hellsing K. Cystic fibrosis detection by means of a test-strip. Pediatrics. Jan 1975;55(1):35-8. [Medline].

  105. Steven LC, Gavel G, Young D, Carachi R. Immunoreactive trypsin levels in neonates with meconium ileus. Pediatr Surg Int. Mar 2006;22(3):236-9. [Medline].

  106. Sung V, Hutson J. A novel way to diagnose cystic fibrosis in the neonate with a bowel obstruction and possible meconium ileus. J Paediatr Child Health. Dec 2003;39(9):720. [Medline].

  107. Swenson O. Pediatric Surgery. 2nd ed. 1962.

  108. Tsui LC. Cystic Fibrosis Mutation Database. 2005;[Full Text].

  109. Vinograd I, Mogle P, Peleg O, et al. Meconium disease in premature infants with very low birth weight. J Pediatr. Dec 1983;103(6):963-6. [Medline].

  110. Welsh MJ, Anderson MP, Rich DP, et al. Cystic fibrosis transmembrane conductance regulator: a chloride channel with novel regulation. Neuron. May 1992;8(5):821-9. [Medline].

  111. White H. Meconium ileus: a new roentgen sign. Radiology. 1956;66:567.

  112. Wilcox DT, Borowitz DS, Stovroff MC, Glick PL. Chronic intestinal pseudo-obstruction with meconium ileus at onset. J Pediatr. Nov 1993;123(5):751-2. [Medline].

  113. Wilschanski MA, Rozmahel R, Beharry S, et al. In vivo measurements of ion transport in long-living CF mice. Biochem Biophys Res Commun. Feb 27 1996;219(3):753-9. [Medline].

  114. Wood BP, Katzberg RW, Ryan DH, Karch FE. Diatrizoate enemas: facts and fallacies of colonic toxicity. Radiology. Feb 1978;126(2):441-4. [Medline].

  115. Wrobleski D, Wesselhoeft C. Ultrasonic diagnosis of prenatal intestinal obstruction. J Pediatr Surg. Oct 1979;14(5):598-600. [Medline].

  116. Zeiher BG, Eichwald E, Zabner J, et al. A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest. Oct 1995;96(4):2051-64. [Medline]. [Full Text].

  117. Ziegler MM. Meconium ileus. Curr Probl Surg. Sep 1994;31(9):731-77. [Medline].

  118. Zielenski J, Patrizio P, Corey M, et al. CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet. Oct 1995;57(4):958-60. [Medline].

  119. Zinner MJ, Schwartz SI, Ellis H. Section XV: Pediatrics -Meconium Ileus. Maingot's Abdominal Operations 10th ed. 1997;2088-90.

  120. van Doorninck JH, French PJ, Verbeek E, et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. Sep 15 1995;14(18):4403-11. [Medline]. [Full Text].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

cystic fibrosis, CF, meconium ileus, MI, simple meconium ileus, complicated meconium ileus

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Michael S Irish, MD, Assistant Professor, Department of Surgery, The University of Iowa; Consulting Pediatric Surgeon, Department of Pediatric Surgery, Blank Children's Hospital and Children's Hospital Physicians Group
Michael S Irish, MD is a member of the following medical societies: International Pediatric Endosurgery Group and Sigma Xi
Disclosure: Nothing to disclose.

Coauthor(s)

Philip M Bovet, DO, MPH, Resident, Department of Pediatric Surgery, Blank Children's Hospital
Philip M Bovet, DO, MPH is a member of the following medical societies: American Academy of Osteopathy and American College of Osteopathic Pediatricians
Disclosure: Nothing to disclose.

Medical Editor

Denis Bensard, MD, Director, Pediatric Trauma, Division of Pediatric Surgery, Children's Hospital of Denver; Associate Professor, University of Colorado Health Sciences Center
Denis Bensard, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Surgeons, American Pediatric Surgical Association, Association for Academic Surgery, and Society of University Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Gail E Besner, MD, Professor of Surgery and Pediatrics, Department of Surgery, Ohio State University College of Medicine and Public Health; Director, Pediatric Surgical Research, Department of Surgery, Children's Hospital
Gail E Besner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Burn Association, American College of Surgeons, American Gastroenterological Association, American Medical Association, American Medical Women's Association, American Pediatric Surgical Association, Association for Academic Surgery, Federation of American Societies for Experimental Biology, Society of Critical Care Medicine, Society of Surgical Oncology, and Society of University Surgeons
Disclosure: Nothing to disclose.

CME Editor

H Biemann Othersen Jr, MD, Professor of Surgery and Pediatrics, Emeritus Head, Division of Pediatric Surgery, Medical University of South Carolina
H Biemann Othersen Jr, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Association for the Surgery of Trauma, American Burn Association, American Cancer Society, American College of Surgeons, American Medical Association, American Pediatric Surgical Association, American Society for Parenteral and Enteral Nutrition, American Surgical Association, American Thoracic Society, British Association of Paediatric Surgeons, Pediatric Oncology Group, Society for Surgery of the Alimentary Tract, Society of Critical Care Medicine, South Carolina Medical Association, Southeastern Surgical Congress, Southern Medical Association, Southern Society for Pediatric Research, and Southern Thoracic Surgical Association
Disclosure: Nothing to disclose.

Chief Editor

Marleta Reynolds, MD, Professor of Surgery, Feinberg School of Medicine, Northwestern University; Interim Head, Division of Pediatric Surgery, Department of Surgery, Children's Memorial Hospital of Chicago
Marleta Reynolds, MD is a member of the following medical societies: American Pediatric Surgical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.